Mylan Launches First Generic Version of Vfend® Tablets

Mylan Inc. has launched Voriconazole Tablets, 50 mg and 200 mg, under a previously announced settlement and license agreement with Pfizer Inc. As the Mylan was the first company who have filed a substantially complete ANDA containing a Paragraph IV certification for against Vfend Tablets, Mylan was awarded 180 days of marketing exclusivity.

Voriconazole Tablets are the generic version of Pfizer's Vfend® Tablets, a triazole antifungal agent. This product had U.S. sales of approximately $186 million for the 12 months ending Dec. 31, 2010, according to IMS Health.